The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001225303
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/09/2026
Date registered
Help: Date registered
7/10/2026
Date last updated
Help: Date last updated
11/11/2026
Date data sharing statement initially provided
Help: Data sharing statement date
7/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Phase I clinical study to evaluate the safety and tolerability of VXM-301, a typhoid conjugate vaccine delivered intradermally by high-density microarray patch (HD-MAP) delivery system, in healthy adults aged 18 to 45 years.
Scientific title
Phase I clinical study to evaluate the safety and tolerability of VXM-301, a typhoid conjugate vaccine delivered intradermally by high-density microarray patch (HD-MAP) delivery system, in healthy adults aged 18 to 45 years.
Additional trial identifiers [1] 318228 0
VXM-301-001
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Typhoid fever 343288 0
Condition category
Condition code
Infection 339403 339403 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Vaxxas Pty Ltd (Hamilton, QLD, Australia) (Vaxxas) is developing a vaccine delivery technology using a proprietary high-density microarray patch (HD-MAP) that has thousands of vaccine-coated micro-projections.

Vaccine formulations are coated onto the micro-projections of a liquid crystal polymer (LCP) HD-MAP.

Vaccine formulations coated onto the HD-MAP micro-projections are applied to the skin using an applicator (HD-MAP delivery system). The applicator is a sterile, hand-held, spring-powered device designed to reproducibly apply the HD-MAP to the skin. During administration, the micro-projections breach the stratum corneum to deliver vaccine to the upper dermis and epidermis of the skin, both of which are rich in antigen-presenting cells required to initiate immune responses.

Investigational product will be administered at the investigator site by a trained, qualified, and delegated clinician or study nurse.

For each HD-MAP treatment arm, participants will receive a combination of active and/or inactive HD-MAPs. A total of three HD-MAPs will be applied sequentially, spaced at least three centimetres apart for a 10 second hold time each, during one single administration session:

Treatment arm 1: 8.3 µg Vi-DT typhoid conjugate vaccine; administered intradermally to the skin overlying the deltoid muscle of the participant’s non-dominant arm using one active and two inactive HD-MAPs.

Treatment arm 2: 16.7 µg Vi-DT typhoid conjugate vaccine; administered intradermally to the skin overlying the deltoid muscle of the participant’s non-dominant arm using two active and one inactive HD-MAPs.

Treatment arm 3: 25 µg Vi-DT typhoid conjugate vaccine; administered intradermally to the skin overlying the deltoid muscle of the participant’s non-dominant arm using three active HD-MAPs.
Intervention code [1] 335123 0
Prevention
Description of the comparator or control
Investigational product will be administered at the investigator site by a trained, qualified, and delegated clinician or study nurse.

Treatment arm 4: 0 µg Vi-DT (Placebo); administered intradermally to the skin overlying the deltoid muscle of the participant’s non-dominant arm using three inactive HD-MAPs. A total of three HD-MAPs will be applied sequentially, spaced at least three centimetres apart for a 10 second hold time each, during one single administration session.

Treatment arm 5: 25µg Vi-DT typhoid conjugate vaccine (active comparator); administered via intramuscular injection to the deltoid muscle of the participant's non-dominant arm.
Control group
Placebo

Outcomes
Primary outcome [1] 346607 0
Incidence, severity, and duration of solicited systemic adverse reactions including fever, headache, malaise, myalgia, arthralgia, fatigue, drowsiness, nausea/vomiting, diarrhoea, loss of appetite, and chills from Day 1 through to Day 8. This is a composite primary outcome.
Timepoint [1] 346607 0
Day 1 (post-dose), Day 4, and Day 8.
Primary outcome [2] 346609 0
Incidence, severity and duration of solicited local adverse reactions including erythema, swelling, induration, ecchymosis, and vaccination site pain from Day 1 through to Day 29. This is a composite primary outcome.
Timepoint [2] 346609 0
Baseline before treatment. Assessment 10 minutes after treatment, and 1 hour after treatment on Day 1. Follow-up visits on Day 4, Day 8, Day 14, and Day 29.
Primary outcome [3] 346613 0
Incidence and severity of unsolicited (spontaneously reported) treatment-emergent adverse events from Day 1 through to Day 29. This is a composite primary outcome.
Timepoint [3] 346613 0
Baseline before treatment. Assessment 10 minutes after treatment, and 1 hour after treatment on Day 1. Follow-up visits on Day 4, Day 8, Day 14, and Day 29.
Secondary outcome [1] 466735 0
Incidence and severity of serious adverse events, and medically attended adverse events from Day 1 through to end of study. This is a composite primary outcome.
Timepoint [1] 466735 0
Baseline before treatment. Assessment 10 minutes after treatment, and 1 hour after treatment on Day 1. Follow-up visits on Day 4, Day 8, Day 14, and Day 29. End of study visit on Day 57.
Secondary outcome [2] 467767 0
Clinically significant changes in clinical laboratory safety data from Day 1 through to end of study. This is a primary outcome.
Timepoint [2] 467767 0
Baseline before treatment. Assessment 10 minutes after treatment, and 1 hour after treatment on Day 1. Follow-up visits on Day 4, Day 8, Day 14, and Day 29. End of study visit on Day 57.
Secondary outcome [3] 467770 0
Clinically significant changes in physical (including targeted) examination data from Day 1 through to end of study. This is a primary outcome.
Timepoint [3] 467770 0
Baseline before treatment. Assessment 10 minutes after treatment, and 1 hour after treatment on Day 1. Follow-up visits on Day 4, Day 8, Day 14, and Day 29. End of study visit on Day 57.
Secondary outcome [4] 467772 0
Clinically significant changes in vital signs data from Day 1 through to end of study. This is a primary outcome.
Timepoint [4] 467772 0
Baseline before treatment. Assessment 10 minutes after treatment, and 1 hour after treatment on Day 1. Follow-up visits on Day 4, Day 8, Day 14, and Day 29. End of study visit on Day 57.
Secondary outcome [5] 467776 0
Local skin response through treatment site assessment at 1-hour following administration on Day 1, and at Days 4, 8, 14, 29, and 57. This is a primary outcome.
Timepoint [5] 467776 0
Baseline before treatment. Assessment 1 hour after treatment on Day 1. Follow-up visits on Day 4, Day 8, Day 14, and Day 29. End of study visit on Day 57.
Secondary outcome [6] 467779 0
Concomitant medication usage. This is a primary outcome.
Timepoint [6] 467779 0
Day 1 to Day 57.
Secondary outcome [7] 467780 0
GMT of serum antibody response to Vi, as assessed by ELISA, at baseline and at Days 8, 14, 29, and 57. This is an exploratory outcome.
Timepoint [7] 467780 0
Baseline, Day 8, Day 13, Day 29, Day 57.
Secondary outcome [8] 467781 0
Seroconversion rate, defined as the proportion of participants with a 4-fold risk in the anti-Vi IgG titre at Days 8, 14, 29, and 57 as compared to baseline values. This is an exploratory outcome.
Timepoint [8] 467781 0
Baseline, Day 8, Day 14, Day 29, Day 57.
Secondary outcome [9] 467782 0
Seroconversion rates at Days 8, 14, 29, and 57 for the HD-MAP (active) treatment arms compared to the active comparator IM injection treatment arm (standard adult dose). This is an exploratory outcome.
Timepoint [9] 467782 0
Day 8, Day 14, Day 29, Day 57.

Eligibility
Key inclusion criteria
To be eligible to participate in this study, an individual must meet all the following criteria:
1) Aged 18 to 45 years (inclusive) at the time of consent;
2) Body mass index (BMI) within the range 18.0 to 32.0 kg/m² (inclusive) during screening period;
3) Being in good health, as determined by satisfactory physical examination, vital signs, 12-lead ECG, laboratory evaluation, stable medical history, and clinical judgment of the Principal Investigator/Investigator;
Participants with stable, chronic underlying illnesses such as psychiatric/psychological disorders, hypertension, diabetes, ischemic heart disease, or hypothyroidism (or other conditions as per investigator’s discretion) may be enrolled at the discretion of the Investigator based on potential clinical significance to the study, and provided their signs and symptoms are controlled.
4) If on regular prescription medication, the medication dose must have been stable for at least three months prior to Screening. Participants with any autoimmune disease, including autoimmune mediated hypothyroidism such as Hashimoto’s disease, linked to listed medical conditions shall not be enrolled in the study.
5) Adequate venous access in left or right arm to allow collection of small-volume blood samples at different visits;
6) Participants of childbearing potential must return a negative pregnancy test at Screening (serum) and pre-dose on Day 1 (urine), and must agree to remain sexually abstinent, use medically effective contraception or have a partner who is sterile or same-sex, from Screening through to EoS. The use of medically effective contraception or IUD must be stable for at least three months prior to Screening. Female participants who are surgically sterile (e.g., having undergone a total hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or postmenopausal with at least 12 months amenorrhoea not considered to be caused by any other medical condition, are not subject to a pregnancy test; If not surgically sterilised, sexually active male participants with a female partner of childbearing potential must agree to use condoms, together with medically effective contraception for their female partner from Screening through to EoS.
7) Participant is able to communicate effectively with study personnel and is considered likely to be reliable, willing and cooperative in terms of compliance with the protocol requirements;
8) Participant is able and willing to provide written, personally signed, informed consent to participate in the study.
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study:
1) Participants who have received any registered or investigational vaccine within 30 days prior to Day 1, except for inactivated influenza vaccine and COVID-19 vaccine, which may be received up to but not including 14 days prior to Day 1;
2) Participants who have previously received a typhoid vaccine within a period of 10 years at the time of consenting;
3) Planned administration of any registered vaccine for the duration of the study;
4) Birthmarks, tattoos, wounds, scars, moles, blemishes, heavy hair or other skin conditions (such as eczema) at the planned vaccination sites (three adjacent sites overlying the deltoid muscle which are at least 3 cm apart) that could be expected to obscure the observation of treatment site reactions;
5) Known chronic spontaneous urticaria or dermographism;
6) Known predisposition to keloid-scar formation (participants who have developed a scar caused by BCG vaccine can be included in the study);
7) History of severe hypersensitivity, anaphylaxis, angioedema, or other significant allergic reaction that, in the opinion of the investigator, may increase risk from receipt of the investigational vaccine;
8) Previous ascertained or suspected disease caused by S. Typhi;
9) Household contact with and/or intimate exposure to an individual with laboratory-confirmed S. Typhi.
10) History of convulsions, epilepsy, or other physician diagnosed central nervous system diseases, excluding febrile convulsions experienced as a child that are considered resolved;
11) History of clinically significant haematological, gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, or psychiatric disease, that, at the discretion of the Investigator, precludes the participant from the study;
12) Presence of abnormal routine laboratory values at Screening which have been deemed as clinically significant by the Investigator;
13) Presence of active viral or bacterial infection, acute illness, with or without fever (tympanic temperature greater than or equal to 37.5 °C), at Day 1 or within 72 hours prior to study vaccination, if determined by the Investigator to be of clinical significance. Enrolment may be deferred for up to one week provided participant remains otherwise eligible and the total Screening period does not exceed 28 days;
14) History of any haematological malignancy or active neoplastic disease (non-melanoma skin cancer that was successfully treated within the 5-year period can be included in the study). Cervical carcinoma in situ, ductal carcinoma in situ even if fully treated is an exclusion. Active is defined as having received treatment within the five years prior to Screening;
15) Presence of an active medical condition, defined as a condition under current evaluation or treatment, that is considered clinically significant by the Investigator, or a recent illness that is considered clinically significant by the Investigator;
16) Planned surgery requiring a general anaesthetic, or surgery requiring inpatient hospitalisation for at least 24 hours during the entire study period;
17) History of illness and/or infection with Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV), or a positive test for Hepatitis B surface antigen, Hepatitis C, or antibodies against HIV at Screening;
18) History of abnormal bleeding, uncontrolled coagulopathy, blood disorders, and/or thrombophlebitis unrelated to venepuncture or intravenous cannulation;
19) History of autoimmune or autoinflammatory immune-mediated medical conditions (including but not limited to coeliac disease);
20) Receiving current chronic treatment with immunosuppressive therapy, including chronic use (more than 14 continuous days) of systemic corticosteroids (cut-off dose >=20mg/day prednisone or equivalent) within 30 days prior to Day 1 including intramuscular steroid injections. The use of inhaled or nasal glucocorticoids or intraarterial steroid injections will be permitted;
21) Known history of immune function disorders including immunodeficiency diseases, or historic chronic use (1 year prior from date of consenting) of systemic steroids (>20 mg/day prednisone equivalent for periods exceeding 14 days), cytotoxic or other immunosuppressive drugs;
22) Participants who have received immunoglobulins and/or any blood or blood products within three months prior to Day 1 or plan to receive any blood or blood products at any time during the study;
23) Participants who have donated blood or plasma, or have had clinically significant blood loss, within 14 days prior to Day 1;
24) Female participants who are pregnant or breast-feeding, or who intend to become pregnant, from Screening through EoS;
25) A history of alcohol or drug abuse in the past 12 months from screening, or a declared alcohol consumption >4 standard drinks per day for 7 days per week (one standard drink is equivalent to 285 mL of full-strength beer, 100 mL of wine, or 30 mL of spirits);
26) Use of any prescription medication (with the exception of contraceptives, hormone replacement therapy, or stable doses of medication required for the management of stable, chronic underlying illnesses) within seven days prior to Day 1;
27) Use of any investigational drug or device within 30 days, or five half-lives of the drug (whichever is longer) before Day 1, or planned use of another investigational drug or device at any time during the study;
28) Participants who are an employee or a first-degree family member of an employee of the Sponsor, the Contract Research Organisation conducting this study, or the study site involved in this study.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation using an e-CRF/interactive web response system.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Block randomisation will be applied for all treatment arms.

Additionally, sex stratification will be applied so that at least 30% of enrolled participants will be male and at least 30% will be female and race stratification will be applied so that at least 15% of enrolled participants will consist of non-white participants.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis
As an initial Phase I clinical study, the sample size of 15 participants per active treatment arm, 15 participants for the inactive treatment arm, and 15 participants for the active comparator treatment arm, totalling 75 participants overall, was based on empirical considerations and no formal sample size calculation was performed.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 30054 0
University of the Sunshine Coast Clinical Trials Centre - Sippy Downs - Sippy Downs
Recruitment hospital [2] 30055 0
University of the Sunshine Coast Clinical Trials Centre - South Bank - South Brisbane
Recruitment postcode(s) [1] 46447 0
4556 - Sippy Downs
Recruitment postcode(s) [2] 46448 0
4101 - South Brisbane

Funding & Sponsors
Funding source category [1] 322788 0
Commercial sector/Industry
Name [1] 322788 0
Vaxxas Pty Ltd
Country [1] 322788 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Vaxxas Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325718 0
None
Name [1] 325718 0
Address [1] 325718 0
Country [1] 325718 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321228 0
Bellberry Human Research Ethics Committee H
Ethics committee address [1] 321228 0
Ethics committee country [1] 321228 0
Australia
Date submitted for ethics approval [1] 321228 0
11/08/2026
Approval date [1] 321228 0
28/09/2026
Ethics approval number [1] 321228 0
2026-08-1356

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153078 0
Dr Nischal Sahai
Address 153078 0
University of the Sunshine Coast Clinical Trials, Building A4, SW1 Complex, 52 Merivale Street, South Brisbane 4101, Queensland
Country 153078 0
Australia
Phone 153078 0
+61 7 5456 3978
Fax 153078 0
Email 153078 0
Contact person for public queries
Name 153079 0
Dr. Angus Forster
Address 153079 0
Vaxxas Pty Ltd, 240 MacArthur Avenue, Hamilton 4007, Queensland
Country 153079 0
Australia
Phone 153079 0
+61 7 2139 5400
Fax 153079 0
Email 153079 0
Contact person for scientific queries
Name 153080 0
Dr. Angus Forster
Address 153080 0
Vaxxas Pty Ltd, 240 MacArthur Avenue, Hamilton 4007, Queensland
Country 153080 0
Australia
Phone 153080 0
+61 7 2139 5400
Fax 153080 0
Email 153080 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.